<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Refined disease risk index for survival after allogeneic hematopoietic cell transplantation (HCT)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Refined disease risk index for survival after allogeneic hematopoietic cell transplantation (HCT)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Refined disease risk index for survival after allogeneic hematopoietic cell transplantation (HCT)</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="4">Disease type and stage</td> <td class="subtitle1_left">Risk group</td> </tr> <tr> <td class="divider_bottom indent1" rowspan="21">Leukemia/MDS/MPN</td> <td colspan="2" rowspan="2">CLL/SLL</td> <td>CR or PR</td> <td>Low</td> </tr> <tr> <td>Stable or progressive</td> <td>Intermediate</td> </tr> <tr> <td colspan="2" rowspan="3">CML</td> <td>Chronic phase</td> <td>Low</td> </tr> <tr> <td>Accelerated phase</td> <td>Intermediate</td> </tr> <tr> <td>Blast crisis</td> <td>Very high</td> </tr> <tr> <td rowspan="6">AML</td> <td rowspan="2">Favorable cytogenetics</td> <td>CR</td> <td>Low</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td rowspan="2">Intermediate cytogenetics</td> <td>CR</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td rowspan="2">Adverse cytogenetics</td> <td>CR</td> <td>High</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>Very high</td> </tr> <tr> <td colspan="2" rowspan="3">ALL</td> <td>First CR</td> <td>Intermediate</td> </tr> <tr> <td>Second or third CR</td> <td>High</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>Very high</td> </tr> <tr> <td rowspan="3">Low-risk MDS (&lt;5 percent blasts)</td> <td>Intermediate cytogenetics</td> <td>Any stage</td> <td>Intermediate</td> </tr> <tr> <td rowspan="2">Adverse cytogenetics</td> <td>Early stage</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td rowspan="3">High-risk MDS (≥5 percent blasts)</td> <td rowspan="2">Intermediate cytogenetics</td> <td>Early stage</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td>Adverse cytogenetics</td> <td>Any stage</td> <td>High</td> </tr> <tr class="divider_bottom"> <td colspan="2">MPN</td> <td>Any stage</td> <td>Intermediate</td> </tr> <tr> <td class="divider_bottom indent1" rowspan="11">Lymphoma</td> <td colspan="2">Hodgkin lymphoma</td> <td>CR</td> <td>Low</td> </tr> <tr> <td colspan="2" rowspan="3">Mantle cell lymphoma</td> <td>CR</td> <td>Low</td> </tr> <tr> <td>PR</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td colspan="2">Clinically indolent B cell NHL</td> <td>CR or PR</td> <td>Low</td> </tr> <tr> <td colspan="2" rowspan="2">Clinically aggressive B cell NHL</td> <td>CR or PR</td> <td>Intermediate</td> </tr> <tr> <td>Induction failure or active relapse</td> <td>Very high</td> </tr> <tr> <td colspan="2" rowspan="2">Burkitt lymphoma</td> <td>CR</td> <td>High</td> </tr> <tr> <td>PR, induction failure, or active relapse</td> <td>Very high</td> </tr> <tr> <td class="divider_bottom" colspan="2" rowspan="2">T cell NHL</td> <td>CR or PR</td> <td>Intermediate</td> </tr> <tr class="divider_bottom"> <td>Induction failure or active relapse</td> <td>High</td> </tr> <tr> <td class="indent1 divider_bottom" colspan="3" rowspan="2">Multiple myeloma</td> <td>CR or PR</td> <td>Intermediate</td> </tr> <tr class="divider_bottom"> <td>Relapsed/refractory disease</td> <td>High</td> </tr> <tr> <td class="subtitle1_left">Risk group</td> <td class="subtitle1_left" colspan="2">Percentage of cases</td> <td class="subtitle1_left" colspan="2">Estimated two-year overall survival (95% CI)</td> </tr> <tr> <td class="indent1">Low</td> <td colspan="2">14</td> <td colspan="2">66 percent (63 to 68 percent)</td> </tr> <tr> <td class="indent1">Intermediate</td> <td colspan="2">63</td> <td colspan="2">51 percent (50 to 52 percent)</td> </tr> <tr> <td class="indent1">High</td> <td colspan="2">20</td> <td colspan="2">33 percent (31 to 35 percent)</td> </tr> <tr> <td class="indent1">Very high</td> <td colspan="2">4</td> <td colspan="2">23 percent (20 to 27 percent)</td> </tr> </tbody></table></div><div class="graphic_lgnd">A refined disease risk index (DRI) was created by the Center for International Blood and Marrow Transplant Research (CIBMTR) based on data from 13,131 patients who underwent myeloablative, nonmyeloablative, or reduced intensity conditioning followed by allogeneic HCT between 2008 and 2010. The DRI combines information on disease type and status in order to identify "low", "intermediate", "high", and "very high" risk patient populations with significantly different estimated overall survival at two years. For AML, t(8;21), inv(16), and t(15;17) were classified as favorable cytogenetics, complex karyotype (4+ abnormalities) as adverse cytogenetics, and all others as intermediate; for MDS, abnormal chromosome 7 and complex karyotype (≥4 abnormalities) were classified as adverse cytogenetics, and all others as intermediate.</div><div class="graphic_footnotes">MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasms; CLL: chronic lymphocytic leukemia; SLL: small lymphocytic lymphoma; CR: complete remission; PR: partial remission; CML: chronic myeloid leukemia; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; HCT: hematopoietic cell transplantation.</div><div class="graphic_reference">Data from: Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR. Blood 2014; 123:3664.</div><div id="graphicVersion">Graphic 95118 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
